SaporinToxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity

Prostate

Volumn 70, Issue 12, 2010, Pages 1286-1294

  Kuroda, Kenji ^a   Liu, He ^b   Kim, Sae ^b   Guo, Ming ^b   Navarro, Vincent ^b   Bander, Neil H ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antibody; Immunotoxin; Prostate cancer; Prostate specific membrane antigen; Saporin

Indexed keywords

ANTIBODY CONJUGATE; HJ591 SAZAP CONJUGATE; IMMUNOTOXIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; PROSTATE SPECIFIC ANTIGEN; RIBOSOME INACTIVATING PROTEIN 1; SAPORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BINDING AFFINITY; BIOTINYLATION; CANCER CELL CULTURE; CELL STRAIN LNCAP; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR XENOGRAFT; ANIMAL; CELL MEMBRANE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MORTALITY; NUDE MOUSE; ORCHIECTOMY; PROSTATE TUMOR; TUMOR CELL LINE; UNITED STATES; XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BIOTINYLATION; CELL LINE, TUMOR; CELL MEMBRANE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MALE; MICE; MICE, NUDE; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; TRANSPLANTATION, HETEROLOGOUS; UNITED STATES;

EID: 77956388275     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21164     Document Type: Article

References (28)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin 2007;57(1):43-66.
2. Klein EA, Kupelian PA. Localized prostate cancer: Radiation or surgery? Urol Clin North Am 2003;30(2):315-330, ix.
3. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer 2002;2(5):389-396.
4. Gulley J, Dahut WL. Chemotherapy for prostate cancer: Finally an advance! Am J Ther 2004;11(4):288-294.
5. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15):1513-1520.
6. Schulke N, Varlamova OA, Donovan GP, Ma D, Gardner JP, Morrissey DM, Arrigale RR, Zhan C, Chodera AJ, Surowitz KG, Maddon PJ, Heston WD, Olson WC. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci USA 2003;100(22):12590-12595.
7. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ. Crystal structure of prostate-specific membraneantigen, a tumor marker and peptidase. Proc Natl Acad Sci USA 2005;102(17):5981-5986.
8. Ross JS, Sheehan CE, Fisher HA, Kaufman RP Jr, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003;9(17):6357-6362.
9. Su SL, Huang IP, Fair WR, Powell CT, Heston WD. Alternatively spliced variants of prostate-specific membrane antigen RNA: Ratio of expression as a potential measurement of progression. Cancer Res 1995;55(7):1441-1443.
10. Liu H, Rajasekaran AK, Moy P, Xia Y, Kim S, Navarro V, Rahmati R, Bander NH. Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res 1998; 58(18):4055-4060.
11. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. Immunotoxin therapy of cancer. Nat Rev Cancer 2006;6(7):559-565.
12. Kreitman RJ. Immunotoxins for targeted cancer therapy. AAPS J 2006;8(3):E532-E551.
13. Stirpe F, Barbieri L, Battelli MG, Soria M, Lappi DA. Ribosome-inactivating proteins from plants: Present status and future prospects. Biotechnology (N Y) 1992;10(4):405-412.
14. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res 1997;57(17):3629-3634.
15. Zheng JY, Chen D, Chan J, Yu D, Ko E, Pang S. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A. Cancer Gene Ther 2003;10(10): 764-770.
16. Bander NH, Trabulsi EJ, Kostakoglu L, Yao D, Vallabhajosula S, Smith-Jones P, Joyce MA, Milowsky M, Nanus DM, Goldsmith SJ. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol 2003;170(5):1717-1721. (Pubitemid 37254913)
17. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005;23(21):4591-4601.
18. Olafsen T, Gu Z, Sherman MA, Leyton JV, Witkosky ME, Shively JE, Raubitschek AA, Morrison SL, Wu AM, Reiter RE. Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody. J Immunother 2007;30(4):396-405.
19. Yip WL, Weyergang A, Berg K, Tonnesen HH, Selbo PK. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells. Mol Pharm 2007;4(2):241-251.
20. Siva AC, Wild MA, Kirkland RE, Nolan MJ, Lin B, Maruyama T, Yantiri-Wernimont F, Frederickson S, Bowdish KS, Xin H. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 2008;68(10):3759-3766.
21. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002;62(24):7190-7194.
22. Fracasso G, Bellisola G, Cingarlini S, Castelletti D, Prayer-Galetti T, Pagano F, Tridente G, Colombatti M. Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 2002;53(1):9-23.
23. Zhao XY, Liu HL, Liu B, Willuda J, Siemeister G, Mahmoudi M, Dinter H. Tomoregulin internalization confers selective cytotoxicity of immunotoxins on prostate cancer cells. Transl Oncol 2008;1(2):102-109.
24. Thrush GR, Lark LR, Clinchy BC, Vitetta ES. Immunotoxins: An update. Annu Rev Immunol 1996;14:49-71.
25. Hu RG, Zhai QW, He WJ, Mei L, Liu WY. Bioactivities of ricin retained and its immunoreactivity to anti-ricin polyclonal antibodies alleviated through pegylation. Int J Biochem Cell Biol 2002;34(4):396-402.
26. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ. A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res 2004;64(21):7995-8001.
27. Ma D, Hopf CE, Malewicz AD, Donovan GP, Senter PD, Goeckeler WF, Maddon PJ, Olson WC. Potent antitumor activity of an auristatin-conjugated, fullyhumanmonoclonal antibody to prostate-specific membrane antigen. Clin Cancer Res 2006;12(8): 2591-2596.
28. Galsky MD, Eisenberger M, Moore-Cooper S, Kelly WK, Slovin SF, DeLaCruz A, Lee Y, Webb IJ, Scher HI. Phase I trial of the prostate-specific membrane antigen-directed immuno-conjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J Clin Oncol 2008;26(13): 2147-2154.